Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A sulfonamide allergy label before solid organ transplantation is associated with significantly higher rates of bacterial infections within one year post-transplant. A retrospective study of nearly 4,000 matched patients found elevated risks for UTIs, skin infections, respiratory infections, and sepsis. Researchers suggest these findings point to an underappreciated protective role for trimethoprim-sulfamethoxazole beyond just preventing opportunistic infections.
A new study presented at the ACAAI Annual Scientific Meeting reveals that solid organ transplant recipients who carry a sulfonamide allergy label before surgery face meaningfully higher risks of bacterial infections in the year that follows. Researchers analyzed nearly 4,000 propensity-matched patients from the TriNetX U.S. Collaborative Network database — half with a pre-transplant sulfonamide allergy label, half without — and found consistently elevated infection rates across multiple categories in the labeled group.
The findings suggest that sulfonamide allergy labels may be leading clinicians to avoid trimethoprim-sulfamethoxazole (TMP-SMX), a drug that may play a broader protective role in transplant patients beyond just preventing opportunistic infections. Tools like the SULF-FAST decision rule could help clinicians better risk-stratify patients carrying these labels.
By the Numbers:
Why it matters: Antibiotic allergy labels — even inaccurate ones — can quietly shape prescribing decisions and patient outcomes. For immunocompromised transplant recipients, revisiting and potentially delabeling sulfonamide allergies could reduce infection burden and improve cost-effective care.